Exciting Participation of NANOBIOTIX in Investor Conferences
NANOBIOTIX, a pioneering biotechnology company focused on innovative cancer treatments, is gearing up for a series of significant investor conferences. This participation underscores the company’s commitment to not only advancing its engagements within the investment community but also promoting its groundbreaking research in nanotechnology aimed at revolutionizing cancer care.
Key Conferences and Presentations Scheduled
This November, NANOBIOTIX will feature prominently at multiple conferences, showcasing its promising clinical developments.
UBS Global Healthcare Conference
The first event on the roster is the UBS Global Healthcare Conference on November 10, where Bart van Rhijn, the Chief Financial & Business Officer of NANOBIOTIX, will present. Scheduled for 5pm ET (11pm CET), this session will provide investors insights into the company’s financial strategies and innovations in therapeutic options.
Guggenheim’s Annual Healthcare Innovation Conference
Simultaneously, Laurent Levy, the Chief Executive Officer, will be presenting at the Guggenheim’s Annual Healthcare Innovation Conference earlier that same day at 4:30pm ET (10:30pm CET). This session serves as an excellent opportunity for the audience to learn about NANOBIOTIX's unique approaches to treating cancer.
Stifel Healthcare Conference
Later in the week, on November 13, the Stifel Healthcare Conference will welcome both Laurent Levy and Bart van Rhijn at 8am ET (2pm CET) in New York City. Their joint presentation aims to highlight NANOBIOTIX’s innovative technologies and the potential impact on oncology treatments.
Webcasting and Replay Details
All these presentations will be webstreamed live, ensuring that investors can catch the insights directly from these leading figures. For those unable to attend live, replays of the presentations will be available, making it easier for interested parties to stay informed about the advancements and strategies discussed.
About NANOBIOTIX and Its Vision
Founded in 2003, NANOBIOTIX aims to expand treatment horizons through advanced nanotechnology. Headquartered in Paris and listed on both Euronext and the Nasdaq, the company is known for its physics-based therapeutic approaches that promise to reshape treatment standards for patients globally.
NANOBIOTIX holds over 25 patent families related to different nanotechnology platforms, with applications spanning oncology, bioavailability, and neurologic disorders. This extensive portfolio signifies the company’s potential to lead in innovative treatments, addressing crucial unmet needs in medicine.
The organization's mission underscores a profound understanding of science's role in enhancing human life, pushing the boundaries of what's achievable in therapeutic development.
Contact Information for Further Inquiry
For additional information regarding NANOBIOTIX's initiatives, their communications and investor relations teams are readily available.
Communications Department
Brandon Owens, VP of Communications, can be reached at +1 (617) 852-4835 or via email at contact@nanobiotix.com.
Investor Relations Department
For inquiries related to investment, Joanne Choi (US) can be contacted at +1 (713) 609-3150, and Ricky Bhajun (EU) at +33 (0) 79 97 29 99. Their email for investor relations is investors@nanobiotix.com.
Frequently Asked Questions
What is NANOBIOTIX’s primary focus?
NANOBIOTIX focuses on advancing nanotherapeutic approaches for the treatment of cancer and other significant diseases.
When are the upcoming conferences for NANOBIOTIX?
NANOBIOTIX will participate in the UBS Global Healthcare Conference on November 10 and the Stifel Healthcare Conference on November 13.
Who are the key speakers from NANOBIOTIX at these events?
Bart van Rhijn and Laurent Levy are the key speakers representing NANOBIOTIX at these conferences.
How can I access the presentations?
The presentations will be live-streamed and available for replay on the company's events page.
What is NANOBIOTIX's vision in the biotechnology sector?
NANOBIOTIX aims to push the boundaries of traditional treatment approaches to expand possibilities for improving patient lives through innovative therapies.
